Cited by 35Renal Transplantation Outcomes and TreatmentsTransplantation: Methods and OutcomesOrgan Donation and Transplantation

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients

Muduma, Gorden, Odeyemi, Isaac, Smith-Palmer, Jayne, Pollock, Richard F.·2016·Advances in Therapy

Abstract

Unlabelled Antibody-mediated rejection (AbMR) is a leading cause of late graft loss in kidney transplant recipients, accounting for up to 60% of late graft failures. AbMR manifests as two distinct phenotypes: the first occurs in the immediate post-transplant period in sensitized patients; the second occurs in the late post-transplant period and has been associated with non-adherence to immunosuppression. The present review summarizes the current treatment options for AbMR, its clinical and economic burden, and approaches for reducing the risk of AbMR. While AbMR is typically refractory to treatment with corticosteroids, there are numerous other approaches focused on removal, inhibition or neutralization of donor-specific antibodies, or inhibition of complement-mediated allograft damage. AbMR treatment is generally expensive with one US study reporting costs of USD 49,000-155,000 per episode. However, leaving AbMR untreated puts patients at high risk of capillaritis, microangiopathy, necrosis and graft failure, which may ultimately result in much greater costs associated with a return to dialysis. Given the barriers to treatment, which include the high cost and the fact that pharmacologic treatments are currently used off-label, prevention of AbMR is important, with improvement in patient adherence to immunosuppression a key strategic approach that may be worthy of further evaluation.Funding Astellas Pharma EMEA Limited.

Integrity signals

Registry

Crossref · 10.1007/s12325-016-0292-y

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Muduma, G., Odeyemi, I., Smith-Palmer, J., & Pollock, R. F.
Affiliations
Astellas Pharma (United Kingdom) (GB)
Corresponding author
Muduma, Gorden
Venue
Advances in Therapy
Published
2016-02-23
Volume
33
Issue
3
Pages
345-356
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W2281327633
Cited by
35
References
53
Citations by year
2026: 3 · 2025: 6 · 2024: 6 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 1
FWCI
0.47
Type
journal article
Language
en
Open access
closed
Locations
  • Advances in Therapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
Astellas Pharma Europe
Topics
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
Keywords
antibody-mediated rejection, kidney transplantation, graft loss, donor-specific antibodies, immunosuppression adherence, treatment costs, off-label drug use, graft failure prevention, capillaritis
MeSH terms
Adult, Female, Graft Rejection, Humans, Middle Aged, Retrospective Studies, Kidney Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review